Przypisy
- ↑ Filipowicz-Sosnowska A. Leczenie biologiczne w środku chorobach reumatycznych. Przew lek. 5, 27-33. 2004.
- ↑ 2,0 2,1 Travis SPL, Stange EF, Lémann M, et al. European evidence based konsens gorsza połowa the diagnosis and management of Crohn’s disease: current management. Gut. 55, Suppl. 1, i16-i35. 2006.
- ↑ 3,00 3,01 3,02 3,03 3,04 3,05 3,06 3,07 3,08 3,09 3,10 3,11 3,12 3,13 3,14 3,15 Indeks Leków Medycyny Praktycznej. Kraków: Wydawnictwo Medycyna Praktyczna, 2007, ss. 48-49. ISBN 978-83-7430-110-7.
- ↑ Mease PJ. Adalimumab: an anti-TNF broker for the treatment of psoriatic arthritis. Expert Opin Biol Ther. 5, 11, 1491-504. 2005. PMID 16255652.
- ↑ 5,0 5,1 Fenner H. Immunopharmacologic profile and therapeutic prospects of anti-TNF-alpha therapy. Z Rheumatol. 57, 5, 294-7. 1998. PMID 9864833.
- ↑ Seiderer J, Brand S, Dambacher J, e al. Adalimumab in patients with Crohn's disease--safety and efficacy in an open-label single centre study. Aliment Pharmacol Ther. 25, 7, 787-96. 2007. PMID 17373917.
- ↑ 7,0 7,1 7,2 7,3 7,4 7,5 7,6 Informacja o leku na stronie European Medicines Agency.
- ↑ 8,0 8,1 Humira.com.
- ↑ 9,0 9,1 Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, natomiast fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 48, 1, 35-45. 2003. PMID 12528101.
- ↑ Weinblatt ME, Keystone EC, Furst DE, et al. Long term efficacy and safety of adalimumab także methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis. 65, 6, 753-9. 2006. PMID 16308341.
- ↑ Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: i randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 50, 5, 1400-11. 2004. PMID 15146409.
- ↑ Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab dodatkowo methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 54, 1, 26-37. 2006. PMID 16385520.
- ↑ Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, oraz fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant norma antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol. 12, 2563-71. 2003. PMID 14719195.
- ↑ Simpson D, Scott LJ. Adalimumab: in psoriatic arthritis. Drugs. 66, 11, 1487-96, 1497-9. 2006. PMID 16906782.
- ↑ Genovese MC, Mease PJ, Thomson GT, et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol. 34, 5, 1040-50. 2007. PMID 17444593.
- ↑ van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of oraz multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 54, 7, 2136-46. 2006. PMID 16802350.
- ↑ Davis JC Jr, Revicki D, van der Heijde DM, et al. Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from oraz randomized controlled study. Arthritis Rheum. 57, 6, 1050-7. 2007. PMID 17665483.
- ↑ Maksymowych WP, Rahman P, Keystone E, et al. Efficacy of adalimumab in patients with active ankylosing spondylitis: results of the Canadian AS Study. American College of Rheumatology Annual Meeting November 12-17 2005; San Diego USA, abstract 505.
- ↑ 19,0 19,1 Plosker GL, Lyseng-Williamson KA. Adalimumab: in Crohn's disease. BioDrugs. 21, 2, 125-32. 2007. PMID 17402796.
- ↑ Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 130, 2, 323-33. PMID 16472588.
- ↑ 21,0 21,1 Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 132, 1, 52-65. 2007. PMID 17241859.
- ↑ Informacja na stronie Puls Medycyny.
- ↑ Humira.com - About Humira.